Navigation Links
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
Date:1/9/2008

incipal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 115 generic and 25 proprietary products in the U.S. and more than 1,200 products globally outside of the U.S.

Forward-Looking Statements

Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of compet
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barr Confirms Patent Challenge of Focalin(R) XR
2. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
3. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
4. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
5. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
8. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
9. Odyssey Thera Granted U.S. Patent for Animal Imaging
10. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
11. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) October 01, 2014 As the world ... no room for doubt that this century would mark the ... the field of medicine science. The fact that the world ... not unknown to the scientific community. Almost half of these ... therefore can be prevented with medical care and intervention. While ...
(Date:10/1/2014)... The participants committed to not only creating unique business ... adjusting, tweaking and testing virtual models and 3D test ... , “I enjoyed being involved as a judge,” stated ... showed a commendable range exploring the technical capabilities of ... and the creativity of the contestants.” , Array Architects ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 Today ... initial round of grants for the Brain Research ... that aims to develop and revolutionize new methods ... of the human brain. This first round of ... year 2014 was allocated to more than 100 ...
(Date:10/1/2014)... CA (PRWEB) September 30, 2014 ... user-friendly, cost-effective tools to address sales, training and ... has developed innovative mobile applications to turn ... outlining the agency’s latest customized mobile app creations, ... http://www.studiopmg.com/work . , In partnership with Toyota, StudioPMG ...
Breaking Biology Technology:Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3Array Architects Challenges Staff to Create with 3D Printer 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Digital Agency Studio PMG Launches New Case Studies on Website 2
... , , NEWARK, N.J., Aug. ... a specialty chemical technology based Life Science Company announced today ... an impartial blind testing protocol Ygiene(TM) Hospital Grade Antimicrobial was ... , Many of today,s commercially available antimicrobials and ...
... , SUNNYVALE, Calif., Aug. 5 Pharmacyclics, Inc. ... rights offering to purchase up to 22,500,000 shares of the Company,s common ... of 5:00 p.m., EDT, on July 31, 2009. The Company increased the ... 18,750,000 shares to up to 22,500,000 shares. , , ...
... CITY, Aug. 5 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... on endocrine therapy and oncology, will announce its second quarter ... August 11, 2009. The Company will host a conference call ... at 10:00 a.m., Eastern Time. , Participants may access the ...
Cached Biology Technology:BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 2BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 3Pharmacyclics, Inc. Rights Offering Oversubscribed 2Pharmacyclics, Inc. Rights Offering Oversubscribed 3
(Date:10/1/2014)... , Finnland, October 1, 2014 /PRNewswire/ ... Durchbruch im Bereich der Biowissenschaften   ... ein Kommen und Gehen zahlreicher Detektionstechnologien. Einige ... zum goldenen Standard. Die Photonen-Upconversion ist eine ... letzten Jahren mit Begeisterung aufgenommen wurde. Jetzt ...
(Date:10/1/2014)... , October 1, 2014 ... in the life science field  The ... come and go over the years. Some are ... Photon upconversion is a novel detection technology that ... years. Now, finally, this technology is becoming commercially ...
(Date:10/1/2014)... prairies and forests of the world can also be ... to a surprising new study led by Colorado State ... The research team analyzed 596 soil samples collected from ... diversity of below-ground life, most of which had never ... 16.2 percent of the organisms discovered in the park ...
Breaking Biology News(10 mins):Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First-of-a-kind Solution for Utilizing Photon Upconversion 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3
... Springer is launching the Journal of Environmental ... the Association for Environmental Studies and Sciences (AESS). ... in print and on Springer,s online platform www.springerlink.com ... Sciences provides a peer-reviewed, academically rigorous and professionally ...
... This release is available in Spanish . ... was a significant step in knowing the causes of cancer better, ... protein in the cells known as SIRT3, induces the proliferation of ... a therapeutic target in the development of effective therapies for cancer. ...
... Access to Research Careers) Program has announced the travel ... of The American Association of Immunologists (AAI) to be ... These awards are meant to promote the entry ... mainstream of the basic science community and to encourage ...
Cached Biology News:Discovery of protein that alters nutrition of breast cancer cells 2Discovery of protein that alters nutrition of breast cancer cells 3MARC travel awards announced for Immunology 2011 2MARC travel awards announced for Immunology 2011 3
Request Info...
Polyclonal Antibody to SHPRH...
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Mouse Wnt-9b Biotinylated Affinity Purified PAb ENTREZ GeneID: 22412...
Biology Products: